TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Adherence to Light Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \[1\] Outpatients 19 to 65 years of age;~* \[2\] Diagnostic and Statistical Manual (DSM)-5 criteria for major depressive disorder (MDD) past or recurrent episode as determined by the Mini International Neuropsychiatric Interview;~* \[3\] taking an antidepressant for no more than six months;~* \[4\] participant desire to discontinue antidepressant treatment because of adverse effects or other reasons;~* \[5\] total score ≤10 on the clinician-rated Montgomery-Asberg Depression Rating Scale \[MADRS\];~* \[6\] Willing and able to complete self-report and online assessments including sufficient fluency in English.~Exclusion Criteria:~* \[1\] Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime);~* \[2\] MDD with psychotic features (lifetime);~* \[3\] significant personality disorder diagnosis \[e.g., borderline, antisocial\];~* \[4\] High suicidal risk, defined by clinician judgment;~* \[5\] History of drug or alcohol abuse, with a severity of at least moderate or severe within 6 months before screening;~* \[6\] Significant neurological disorders, head trauma, or other unstable medical conditions;~* \[7\] regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers);~* \[8\] history of severe withdrawal effects with antidepressant discontinuation;~* \[9\] retinal disease or other eye condition preventing use of bright light therapy;~* \[10\] use of photosensitizing medication within 1 week of baseline visit.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Light therapy (Type: OTHER): Daily exposure on weekdays to a standard light device (e.g., fluorescent light box such as the Carex Day-Light Classic, emitting 4000 Kelvin white light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter) for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am. Participants will also taper and discontinue their antidepressant medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 and no older than 65 on the day of first dosing~* healthy~* Quetelet Index (Body Mass Index) of 18 to 30 kg/m2~* In general, results of haematology and chemistry should be within the laboratory's reference ranges. Determinants of renal and hepatic function should be within twice the upper limit of normal range.~Exclusion Criteria:~* Documented history of sensitivity / idiosyncrasy to medicinal products or excipients~* history of smoking within the past year~* history of or current abuse of drugs, alcohol and/or solvents~* Current use of any (over the counter) medication potentially influencing heme oxygenase or the cardiovascular system~* Inability to understand the nature and extent of the trial and the procedures required~* Participation to a drug trial within 60 days prior to the first dose~* Febrile illness within 3 days before the first dose~* Heterozygosity (LS) or homozygosity (LL) with regard to the number of GT repeats in the HO-1 promoter region

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): L-arginine treatment first, heme arginate treatment second
- 2 (Type: EXPERIMENTAL): Heme arginate treatment first, L-arginine treatment second

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematologic malignancies or bone marrow failure syndrome who are candidates for allogeneic bone marrow transplantation are eligible for this study. Hematologic malignancies indicated for transplantation:~  * Acute lymphoblastic leukemia (ALL) in first remission (with high risk feature), 2nd or greater remission.~ * Acute myeloid leukemia (AML) in first remission (with high risk feature), 2nd or greater remission.~ * Chronic myeloid leukemia (CML) in 2nd chronic phase or accelerated phase.~ * Juvenile myelomonocytic leukemia (JMML).~ * Myelodysplastic syndrome.~ * Biphenotypic leukemia in first (with high risk feature), 2nd or greater remission.~ * Induction failure leukemia.~ * Refractory relapsed leukemia.~ * Bone marrow failure syndrome.~ * Severe aplastic anemia failed immunotherapy.~* Patients who do not have a 6 out of 6 matched related or unrelated donor or 4/6 and 5/6 matched cord blood will be eligible for this study.~* Partially mismatched related donor availability as defined by molecular typing with 3 to 5 HLA matches.~* Patients who are under 22 years of age.~Exclusion Criteria:~* Patients will not be excluded based on sex, racial, or ethnic background.~* Patients will be excluded if they demonstrate significant functional deficits in major organs, which would obviously interfere with successful outcome following bone marrow transplant utilizing the following guidelines.~  * Evidence of active, deep-seated, life-threatening infections for which there is no known effective therapy (certain fungal species, HIV, etc.).~ * Patients who have been treated for infections must have appropriate responses as documented by 2 (two) consecutive negative cultures and/or stable radiographic examinations.~ * Patients who have active central nervous system (CNS) leukemic disease.~* Patients will be excluded if they are women of childbearing potential who are currently pregnant (beta-HCG+) or who are not practicing adequate contraception.~* Patients who have had a previous hematopoietic stem cell transplant will be excluded.~* Donors will be excluded if they are sensitive to E. coli-derived protein.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Granulocyte Colony Stimulating Factor (G-CSF) stimulation (Type: OTHER): Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 35 years~2. Popliteal artery aneurysm \> 2 cm in diameter with or without presence of mural thrombus~3. Candidate for either OPAR or EPAR as judged by the treating investigator.~4. Greater than 2 cm length of normal superficial femoral artery distal to the deep femoral artery takeoff and \>2 cm length of normal popliteal artery proximal to the first patent tibial artery.~5. Willing to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.~Exclusion Criteria:~1. Popliteal artery thrombosis~2. Popliteal artery aneurysm causing symptomatic thromboembolic disease or compressive symptoms.~3. Superficial femoral artery occlusion or distal tibio-peritoneal occlusion~4. Less than 2 cm length of normal artery to accommodate stent graft seal~5. Life expectancy of less than 2 years.~6. Deemed excessive risk for surgical bypass (defined as prohibitive operative risk by formal pre-procedural cardiac risk assessment undertaken by a cardiologist or internist according to established AHA guideline criteria).~7. A documented hypercoagulable state (defined as a known blood disorder associated with venous or arterial thrombosis).~8. Any infrainguinal revascularization procedure on index leg within 12 weeks prior to treatment initiation.~9. Current immune-suppressive medication, chemotherapy or radiation therapy.~10. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid reaction (laryngospasm, bronchospasm, cardiorespiratory collapse, or equivalent) and which would preclude patient from participation in angiographic procedures.~11. Allergy to stainless steel or nitinol.~12. Pregnancy or lactation.~13. Inability or refusal to provide informed consent.~14. Patients who received an investigational drug for peripheral arterial disease within 4 weeks of screening or who participated in another non-observational clinical trial in the prior 30 days.~15. Prior leg bypass on the ipsilateral limb

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Surgery (Type: ACTIVE_COMPARATOR): In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
- Endovascular Surgical repair (EPAR) (Type: ACTIVE_COMPARATOR): In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the colon or rectum~* Liver metastases~* Inoperable (technical or medical)~* 1-4 metastases~* Maximum 40 mm in diameter~* Suitable for both therapies, RFA and SBRT~Exclusion Criteria:~* Uncontrolled extrahepatic disease and uncontrolled primary cancer~* Liver cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Stereotactic body radiation therapy (Type: EXPERIMENTAL): Colorectal liver metastases treated by SBRT
- Radiofrequency ablation (Type: ACTIVE_COMPARATOR): Colorectal liver metastases treated by RFA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Acupuncture to Improve Function, Exercise Capacity, and Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans eligible for this study are men or women between 25 and 65 years old with non-malignant low back pain greater than 6 months duration and pain scores greater than 4 (on a Numeric Pain Scale of 0 = No Pain and 10 = Worst Imaginable Pain) on most days out of the preceding month.~* Eligible subjects will also need to be able to tolerate 3 minutes walking at a rate of 0.5 miles per hour on a horizontal surface.~Exclusion Criteria:~* Inability to provide informed consent~* Diagnosis of dementia~* Severe depression (Beck Depression Inventory score \> 30), suicidality, or untreated mental illness~* Severe anxiety (Beck Anxiety Inventory score \> 30)~* Evidence of current substance abuse or alcoholism on the TICS~* Ongoing litigation related to the low back pain complaint~* Pregnancy or intent to become pregnant during time of study~* Ambulation requiring an assistive device~* Neurological, orthopedic, or other conditions impairing ambulation that would affect exercise safety~* Progressive neurological changes, altered sensation, or a history of cauda equina syndrome~* Pain below the knee that limits ambulation~* Lower extremity amputation proximal to the toes~* Low back pain problem requiring surgical intervention or impending surgery~* A history of lumbar vertebral fracture; and~* A history of prior lumbar surgery. Additional exclusion criteria include medical conditions that would affect an exercise program, such as rheumatologic, infectious, cardiac, peripheral vascular and pulmonary conditions, or ongoing cancer treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Acupuncture plus Treadmill Exercise (Type: EXPERIMENTAL): Acupuncture plus Treadmill Exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COPD Exacerbation Blood and Urine Biomarkers Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with COPD (FEV1 \<80% AND FEV1/FVC \< 70%)~* Ages 35-80yrs~Exclusion Criteria:~* History of Asthma~* Bronchiectasis~* Carcinoma of the bronchus~* Recent COPD exacerbation or pulmonary infection (less than 1 month)~* Other significant respiratory disease~* Pregnancy

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected patients~* At least 18 years of age~* Males or non-pregnant, non-lactating females~* Documented virological treatment failure on at least 3 classes of antiretroviral drugs~* No adequate antiretroviral therapy possible with currently available antiretroviral agents~* Virological treatment failure is defined as plasma HIV-1 RNA levels \> 5000 while taking at least three different antiretroviral drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous triple-class therapy (Type: ACTIVE_COMPARATOR): Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
- Alternating therapy (Type: EXPERIMENTAL): Patients will be assigned to weekly alternating dual-class regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Timing of Dilation Tracheostomy in Mechanically Ventilated Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD (GOLD stage III or IV)~* Suspected long-time invasive mechanical ventilation due to ARF (\> 10 days)~* Informed consent of the patient or legal guardian~Exclusion Criteria:~* Severe neurological failure (such as stroke, cerebral haemorrhage etc.)~* Immunosuppressant therapy (with the exception of steroid therapy)~* Major risk of bleeding~* Intubation \> 72 h~* Contraindication for dilation tracheotomy~* Impossibility of intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early tracheostomy (Type: EXPERIMENTAL): Percutaneous dilation tracheostomy \< 72h on mechanical ventilation
- Late tracheostomy (Type: EXPERIMENTAL): Percutaneous dilation tracheostomy \> 10 days on mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SNAP 25 Gene Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients will be male or female outpatients who are at least 6 years of age (there is no upper age limit)~2. Patients must meet DSM-IV criteria for ADHD~3. Patients and parents/guardians must have a degree of understanding sufficient to be able to communicate suitably with the investigator and study coordinator~4. Patients must have tolerated the drug at therapeutic doses, but have shown a true lack of improvement in symptoms~5. Must have shown clinically significant superiority in improvement in ADHD symptoms on amphetamine relative to MPH.~Exclusion Criteria:~1. Must not have a true allergy to methylphenidate or amphetamines~2. Must not have a history of serious adverse reactions to methylphenidate

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CPAP to Reduce Arterial Stiffness in Non Sleepy, Moderate to Severe Obstructive Sleep Apnea (STIFFSLEEP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* moderate to severe obstructive sleep apnea, defined as apnea/hypopnea index superior to 15~Exclusion Criteria:~* Epworth sleep scale superior to 16~* other sleep diseases~* moderate or severe lung disease~* cardiac disease other than hypertension~* cerebrovascular diseases~* other vascular diseases~* other chronic diseases except metabolic syndrome

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- OSA w/o EDS (Type: None): Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
- OSA w EDS (Type: None): Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mesenteric Sparing for the Prevention of Recurrent Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Residents of the United States~2. Isolated ileocolic Crohn's disease without evidence of perforation~3. Concurrent therapies with corticosteroids, 5-aminosalicylic acid (5-ASA) drugs, thiopurines, methotrexate (MTX), antibiotics, and anti-tumor necrosis factor (TNF) therapy are permitted~4. All patients should have undergone a colonoscopy and CT enterography in last 3 months to assess severity of disease~5. Have no contraindications to magnetic resonance (MR) evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia~6. Ability to comply with protocol~7. Competent and able to provide written informed consent~8. Medically refractory disease or inability to tolerate ongoing medical therapy~Exclusion Criteria:~1. Inability to give informed consent.~2. Patients undergoing repeat ileocolic resection~3. Patients with concurrent disease in other locations (e.g., proximal stricturing of the small bowel, fistulizing disease to the sigmoid colon) requiring additional operation intervention beyond an ileocolic resection~4. Clinically significant medical conditions within the six months before administration of Mesenchymal Stem Cells (MSCs): e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient~5. Specific exclusions;~   a. Evidence of hepatitis B, C, or HIV~6. History of cancer including melanoma (with the exception of localized skin cancers)~7. Emergent indication for an operation~8. A resident outside the United States~9. Pregnant or breast feeding.~10. History of clinically significant auto-immunity (other than Crohn's disease) or any previous example of fat-directed autoimmunity~11. Inability to follow up at Mayo Clinic at 3 to 4 and 12 months for postoperative imaging and endoscopy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mesenteric sparing ileocolic resection (Type: ACTIVE_COMPARATOR): Ileocolic resection without removal of the lymph nodes in the mesentery.
- High ligation ileocolic resection (Type: ACTIVE_COMPARATOR): Ileocolic resection with removal of lymph nodes in the mesentery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues